Hospital
Florida Hospital Zephyrhills INC
Florida Hospital Zephyrhills INC was paid $9.95M by Medicaid between Jan 2018 and Dec 2024, across 185 billing codes. Its largest line is 99283, emergency room visit (moderate) — 17% of everything it billed.
33Billing provider infoFLORIDA HOSPITAL ZEPHYRHILLS INC
ZEPHYRHILLS, FL 33541
ZEPHYRHILLS, FL 33541
33aNPI1346354677assigned 08/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.95M
24GClaims468,403
24DCodes billed185
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Florida
Rank by total paid#52 of 163
Median peer was paid$4.77M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 43,710 | $393K | |
| 2019 | 111,778 | $1.92M | |
| 2020 | 85,180 | $1.66M | |
| 2021 | 88,109 | $2.08M | |
| 2022 | 71,975 | $1.69M | |
| 2023 | 46,581 | $1.41M | |
| 2024incomplete | 21,070 | $804K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 25,531 | 22,547 | $1.67M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 21,307 | 17,834 | $1.33M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.0% | 11,945 | 9,722 | $698K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 6.1% | 12,065 | 9,850 | $603K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4.7% | 5,388 | 4,381 | $470K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 4.7% | 2,955 | 2,449 | $465K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 3.7% | 4,549 | 3,625 | $370K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 3,016 | 2,509 | $350K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 3.2% | 4,653 | 4,137 | $315K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 4,326 | 3,378 | $298K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.4% | 7,960 | 7,436 | $239K |
| 96361 | Intravenous infusion, hydration; each additional hour | 2.4% | 7,389 | 5,836 | $237K |
173 more codes
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.2% | 3,262 | $215K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 2,982 | $212K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 5,114 | $184K |
| 80053 | Comprehensive metabolic panel | 1.8% | 26,533 | $183K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.5% | 1,570 | $153K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.5% | 8,391 | $149K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 3,304 | $115K |
| 59025 | Fetal non-stress test | 1.1% | 2,575 | $108K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,536 | $97K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 5,790 | $83K |
| 81001 | <1% | 17,665 | $61K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 6,828 | $59K |
| 81025 | <1% | 6,262 | $58K | |
| 71045 | Radiologic examination, chest; single view | <1% | 14,104 | $58K |
| G0378 | Hospital observation service, per hour | <1% | 6,625 | $55K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 555 | $54K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,564 | $52K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,449 | $51K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,534 | $42K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,990 | $38K |
| 73610 | <1% | 939 | $37K | |
| 97597 | <1% | 2,364 | $34K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,848 | $33K |
| 82947 | <1% | 6,848 | $29K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 328 | $28K |
| 86850 | <1% | 1,112 | $28K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 750 | $27K |
| 73630 | <1% | 1,163 | $27K | |
| 01999 | <1% | 1,903 | $27K | |
| 73130 | <1% | 711 | $25K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 930 | $22K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 16,382 | $22K |
| 92587 | <1% | 473 | $20K | |
| 73562 | <1% | 918 | $20K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,359 | $20K |
| 76801 | <1% | 1,213 | $20K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 2,749 | $19K |
| 86901 | <1% | 1,847 | $19K | |
| 73110 | <1% | 383 | $17K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 759 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 31,249 | $17K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,983 | $16K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 102 | $15K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 155 | $15K |
| 73030 | <1% | 534 | $14K | |
| 96376 | <1% | 2,993 | $14K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 231 | $14K |
| 87420 | <1% | 756 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 369 | $12K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 574 | $10K |
| 74022 | <1% | 726 | $10K | |
| 84702 | <1% | 1,900 | $9K | |
| 93971 | <1% | 252 | $9K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 486 | $8K |
| 80050 | General health panel | <1% | 544 | $8K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 986 | $8K |
| 85730 | <1% | 3,937 | $8K | |
| 97163 | <1% | 552 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 12,936 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 220 | $7K |
| 87186 | <1% | 1,750 | $7K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,452 | $7K |
| 85610 | <1% | 4,732 | $7K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 154 | $7K |
| 84484 | <1% | 13,822 | $6K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,243 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 461 | $6K |
| 82077 | <1% | 614 | $5K | |
| 74018 | <1% | 151 | $5K | |
| 85055 | <1% | 2,171 | $5K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 58 | $5K |
| 76830 | Ultrasound, transvaginal | <1% | 129 | $5K |
| 83735 | <1% | 6,389 | $4K | |
| 85027 | <1% | 2,438 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,619 | $4K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,302 | $4K |
| 83880 | <1% | 3,620 | $4K | |
| 72100 | <1% | 261 | $4K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 29 | $4K |
| 87040 | <1% | 5,319 | $4K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 184 | $3K |
| 76642 | <1% | 72 | $3K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,806 | $3K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 326 | $3K |
| 12001 | <1% | 58 | $3K | |
| 80061 | Lipid panel | <1% | 2,289 | $3K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 85 | $2K |
| 73502 | <1% | 103 | $2K | |
| 85379 | <1% | 1,346 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 297 | $2K |
| 12011 | <1% | 27 | $2K | |
| C1769 | Guide wire | <1% | 360 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,997 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,590 | $2K |
| 83690 | <1% | 9,348 | $2K | |
| 84132 | <1% | 229 | $1K | |
| 83605 | <1% | 3,574 | $1K | |
| 82550 | <1% | 2,225 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,731 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,491 | $1K |
| 82746 | <1% | 304 | $1K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 787 | $1K |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 16 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 79 | $1K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,529 | $999.38 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,954 | $956.46 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 36 | $902.25 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,548 | $897.88 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 836 | $892.43 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 105 | $873.72 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,266 | $760.58 |
| 82607 | <1% | 502 | $742.97 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,700 | $741.23 |
| 87077 | <1% | 1,364 | $735.58 | |
| 84145 | <1% | 500 | $703.41 | |
| 94644 | <1% | 126 | $684.62 | |
| 93017 | <1% | 19 | $678.66 | |
| 84439 | <1% | 413 | $602.11 | |
| 72131 | <1% | 72 | $591.16 | |
| 84703 | <1% | 1,472 | $550.51 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 16 | $539.63 |
| 99152 | <1% | 14 | $533.23 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 15 | $518.59 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 510 | $507.18 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 230 | $489.91 |
| 86900 | <1% | 1,851 | $486.03 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 78 | $345.93 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 511 | $293.76 |
| 87210 | <1% | 117 | $270.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,313 | $218.47 |
| 82247 | <1% | 68 | $197.08 | |
| G1010 | Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program | <1% | 87 | $164.67 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 188 | $163.07 |
| 81003 | <1% | 1,330 | $161.93 | |
| 82803 | <1% | 15 | $161.10 | |
| 0002A | <1% | 29 | $158.12 | |
| 71250 | <1% | 12 | $149.00 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 679 | $138.98 |
| 93880 | <1% | 56 | $98.16 | |
| 90715 | <1% | 106 | $95.97 | |
| 0011A | <1% | 73 | $79.74 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 169 | $73.60 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 55 | $52.85 |
| 73080 | <1% | 14 | $38.72 | |
| J2704 | Injection, propofol, 10 mg | <1% | 246 | $34.83 |
| 0012A | <1% | 53 | $30.00 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 89 | $17.76 |
| 0001A | <1% | 24 | $16.94 | |
| 87641 | <1% | 57 | $11.91 | |
| 85652 | <1% | 104 | $10.95 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 46 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 18 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 533 | $0.00 |
| 93458 | 0% | 16 | $0.00 | |
| 82553 | 0% | 116 | $0.00 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 0% | 18 | $0.00 |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 60 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 21 | $0.00 |
| 86141 | 0% | 46 | $0.00 | |
| 99156 | 0% | 18 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 0% | 14 | $0.00 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 20 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 218 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 16 | $0.00 |
| 97167 | 0% | 69 | $0.00 | |
| 97116 | 0% | 22 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 241 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 14 | $0.00 |
| 80179 | 0% | 52 | $0.00 | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 15 | $0.00 |
| 96367 | 0% | 22 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 14 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 24 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCRUNK, DANIEL (CFO)
| Provider | Location | Paid |
|---|---|---|
| Tarpon Springs Hospital Foundation INC | Tarpon Springs, FL | $6.03M |
| Florida Hospital Dade City INC | Dade City, FL | $5.50M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.